CF
RCUS icon

Corebridge Financial’s Arcus Biosciences RCUS Stock Holding History

Corebridge Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,810
Closed -$226K – 2157
2025
Q1 		$226K Sell
28,810
-125
-0.4% -$1.45K ﹤0.01% 1997
2024
Q4 		$431K Sell
28,935
-2,258
-7% -$36.9K ﹤0.01% 1763
2024
Q3 		$477K Sell
31,193
-355
-1% -$5.6K ﹤0.01% 1760
2024
Q2 		$480K Buy
+31,548
New +$509K ﹤0.01% 1714

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Corebridge Financial's RCUS Position: Q2 2025 in Review

Corebridge Financial sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 28,810 shares — an estimated $226K sold.

Corebridge Financial first reported a position in RCUS in Q2 2024 and held it in 4 quarters. The position peaked at $480K in Q2 2024. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Corebridge Financial reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 28,810 Arcus Biosciences shares in Q2 2025, an estimated $226K.
  • Corebridge Financial first reported a position in Arcus Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Arcus Biosciences position peaked at $480K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.